Calls

Funding Foundations

There are numerous funding foundations awarding grants to both academia and SMEs. In this overview we show the most relevant foundations such as the Bill & Melinda Gates Foundation (BMGF), the Michael J. Foxx Foundation (MJFF) and the Alzheimer’s Drug Discovery Foundation (ADDF).

Bill & Melinda Gates Foundation (BMGF)

The Bill & Melinda Gates Foundation (BMGF) is focused on the areas of greatest need, on the ways in which they can do the most good.

The foundation is teaming up with partners around the world to take on some tough challenges: extreme poverty and poor health in developing countries, and the failures of America’s education system. The foundation focusses on specific issues, which are the biggest barriers that prevent people from making the most of their lives.

For each issue they fund innovative ideas that could help remove these barriers:

  • New techniques to help farmers in developing countries grow more food and earn more money
  • New tools to prevent and treat deadly diseases
  • New methods to help students and teachers in the classroom.

There are no open Grant Opportunities at this time.

More about this foundation or visit the Gates foundation website

 


The Michael J. Fox Foundation (MJFF)

Subsidy: $180,000

Scope: Movement disorder specialists (neurologists with subspecialty training in Parkinson’s disease and other movement disorders) serve as an important bridge between scientific advances in the lab and positive patient outcomes in the care setting.

While the demand for movement disorder specialists is increasing, not enough neurologists are receiving this vital training. To address this unmet need, the Michael J. Fox Foundation (MJFF), in collaboration with the Edmond J. Safra Foundation, introduced The Edmond J. Safra Fellowship in Movement Disorders. By funding academic centers to train new movement disorder clinician-researchers, this program aims to develop a network of highly trained specialists to be the next generation of leaders in Parkinson’s research and clinical care.

More about this foundation or visit the MJFF website

 


Alzheimer’s Drug Discovery Foundation (ADDF): Drug Development program

Subsidy: $50,000-100,000 for epidemiological analyses; up to $3,000,000 for clinical trials

Scope: The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.

Specifically, the Prevention Beyond the Pipeline program supports:

  • Studies Leveraging the Consortium of Cohorts for Alzheimer’s Prevention Action (CAPA);
  • Comparative Effectiveness Research;
  • Studies of Cognitive Decline and Cognitive Reserve.

More about this foundation or visit the ADDF website

 


Alzheimer’s Drug Discovery Foundation (ADDF): Program To Accelerate Clinical Trials (PACT)

Subsidy: up to $3,000,000

Scope: The goal of this program is to increase the number of innovative pharmacologic interventions tested in clinical studies for Alzheimer’s disease and related dementias. This includes novel, repurposed, and repositioned drugs as well as natural products. The ADDF is interested in small molecules and biologics (e.g. antibodies, peptides, gene therapies).

Specifically, the PACT program supports:

  1. Early-stage human clinical trials;
  2. Regulatory studies.

More about this foundation or visit the ADDF website

 


Alzheimer’s Drug Discovery Foundation (ADDF): Neuroimaging And CSF Biomarker Development Program

Subsidy: $600,000

Scope: The aim of this program is to develop biomarkers for which there is a clear clinical need in Alzheimer’s disease and related dementias.

Specifically, this program focuses on:

  • Developing novel PET ligands for clinical use
  • Supporting novel CSF biomarkers
  • Validating established MRI approaches in larger cohorts

More about this foundation or visit the ADDF website

 


Alzheimer’s Drug Discovery Foundation (ADDF): Prevention Beyond The Pipeline

Subsidy: $50,000-100,000 for epidemiological analyses; up to $3,000,000 for clinical trials

Scope: The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.

Specifically, the Prevention Beyond the Pipeline program supports:

  • Studies Leveraging the Consortium of Cohorts for Alzheimer’s Prevention Action (CAPA);
  • Comparative Effectiveness Research;
  • Studies of Cognitive Decline and Cognitive Reserve.

More about this foundation or visit the ADDF website

Catalyze Figure Ovals Lightgray
Newsletter

A must-have if you’re interested in getting your business to the next level